Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders

Publisher： Elsevier

ISSN： 1471-4914

Source： Trends in Molecular Medicine, Vol.8, Iss.7, 2002-07, pp. : 319-323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glatiramer acetate treatment does not modify the clinical course of (NZB BXSB)F1 lupus murine model

By Borel Paula Benkhoucha Mahdia Weber Martin S. Zamvil Scott S. Santiago-Raber Marie-Laure Lalive Patrice H.

International Immunology, Vol. 20, Iss. 10, 2008-10 ,pp. : 1313-1319

Oxford University Press

Access to resources Recommend Favorite

Glatiramer acetate (Copaxone(R)) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis

By Kayhan B. Aharoni R. Arnon R.

Immunology Letters, Vol. 88, Iss. 3, 2003-09 ,pp. : 185-192

Elsevier

Access to resources Recommend Favorite

Do T h 2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?

By Jee Youngheun Liu Ruolan Bai Xue-Feng Campagnolo Denise I. Shi Fu-Dong Vollmer Timothy L.

International Immunology, Vol. 18, Iss. 4, 2006-04 ,pp. : 537-544

Oxford University Press

Access to resources Recommend Favorite

Cyclosporine in the treatment of autoimmune disorders: a 10-year experience

By Mitrovic D. Popovic M. Glisic B. Pavlica L. Dimitrijevic M.

Transplantation Proceedings, Vol. 30, Iss. 8, 1998-12 ,pp. : 4134-4134

Elsevier

Access to resources Recommend Favorite

Role of HIF-1 in Iron Regulation: Potential Therapeutic Strategy for Neurodegenerative Disorders

Current Molecular Medicine, Vol. 6, Iss. 8, 2006-12 ,pp. : 883-893

Bentham Science Publishers

Access to resources Recommend Favorite